| Completed | Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed C Healthy Lactating Women | Phase 4 | 2023-08-04 |
| Completed | A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Hypercholesterolemia | Phase 2 | 2023-01-12 |
| Recruiting | Bempedoic Acid Pregnancy Surveillance Program Pregnancy, Hyperlipidemias | — | 2021-09-01 |
| Completed | Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LD Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia | Phase 2 | 2018-05-09 |
| Completed | A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Hyperlipidemias | Phase 3 | 2017-10-23 |
| Completed | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy Hypercholesterolemia | Phase 2 | 2017-04-07 |
| Completed | Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE) Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | Phase 3 | 2017-02-03 |
| Completed | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 Hypercholesterolemia | Phase 2 | 2017-01-19 |
| Completed | Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Wh Cardiovascular Diseases, Statin Adverse Reaction | Phase 3 | 2016-12-22 |
| Completed | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction | Phase 3 | 2016-11-29 |
| Completed | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiova Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | Phase 3 | 2016-11-18 |
| Completed | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction | Phase 3 | 2016-11-16 |
| Completed | Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases | Phase 3 | 2016-01-21 |
| Completed | A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg Hyperlipidemia | Phase 2 | 2015-12-01 |
| Completed | Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension Hypercholesterolemia, Hypertension | Phase 2 | 2014-06-16 |
| Completed | Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy Hypercholesterolemia | Phase 2 | 2014-03-01 |
| Completed | Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002 Hyperlipidemia | Phase 1 | 2013-12-01 |
| Completed | Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients Hypercholesterolemia | Phase 2 | 2013-09-01 |
| Completed | A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects Hypercholesterolemia | Phase 2 | 2012-12-01 |
| Completed | A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance Hypercholesterolemia | Phase 2 | 2012-10-04 |
| Completed | A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes Hyperlipidemia, Type 2 Diabetes | Phase 2 | 2012-04-01 |
| Completed | A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects Safety Evaluation of Escalating Doses | Phase 1 | 2011-10-25 |
| Completed | A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either N Dyslipidemia | Phase 2 | 2010-12-01 |
| Completed | A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia Mild Dyslipidemia | Phase 1 | 2010-04-20 |